The LACOG-0415 phase II trial: abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels

23/05/2019

Articles, Publications, Publications Genitourinary

Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios and André Fay
BMC Cancer

Full link: https://rdcu.be/bDXNy

The LACOG-0415 phase II trial: abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels

Send us a message

Cura Project

The LACOG-0415 phase II trial: abirateroneacetate and ADT versus apalutamide versusabiraterone acetate and apalutamide inpatients with advanced prostate cancerwith non-castration testosterone levels

Related Posts

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

Prevalence of patients with indication of genetic evaluation for hereditary breast and ovarian syndrome in the Brazilian cohort study – AMAZONA III

Comprehensive genomic profiling of non-small cell lung cancer in Brazil (GBOT 0118/LACOG 0418).

Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study